Durvalumab is a PD-L1 inhibitor that is FDA-approved for the treatment of non-small cell lung cancer (NSCLC), extensive-stage small cell lung cancer (SCLC), locally advanced or metastatic urothelial carcinoma, advanced or metastatic biliary tract cancer, hepatocellular carcinoma, endometrial cancer, and as a neoadjuvant therapy for resectable NSCLC (Wilmington, 2024). The gene discussed is CD274; the disease is small cell lung carcinoma.